Crispr Therapeutics (NASDAQ:CRSP) Given “Buy” Rating at William Blair
William Blair reaffirmed their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Thursday morning, AnalystRatings.com reports.
Other analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a buy rating on shares of Crispr Therapeutics in a report on Thursday, January 30th. Needham & Company LLC reaffirmed a buy rating and issued a $84.00 price target on shares of Crispr Therapeutics in a report on Monday, December 23rd. Oppenheimer boosted their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research note on Monday, November 25th. BidaskClub downgraded shares of Crispr Therapeutics from a sell rating to a strong sell rating in a report on Tuesday. Finally, TheStreet raised shares of Crispr Therapeutics from a d rating to a c rating in a research note on Monday, October 28th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $78.29.
Shares of NASDAQ CRSP traded down $2.32 during trading on Thursday, reaching $55.80. 1,623,146 shares of the stock were exchanged, compared to its average volume of 1,113,728. The business’s 50-day moving average price is $57.85 and its 200 day moving average price is $53.01. Crispr Therapeutics has a twelve month low of $30.75 and a twelve month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $3.15 billion, a price-to-earnings ratio of -121.30 and a beta of 3.25.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. 21.40% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. NEXT Financial Group Inc grew its stake in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the period. Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics in the third quarter worth approximately $26,000. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $26,000. Webster Bank N. A. bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $26,000. Finally, Advisory Services Network LLC boosted its holdings in Crispr Therapeutics by 146.0% in the fourth quarter. Advisory Services Network LLC now owns 674 shares of the company’s stock worth $41,000 after acquiring an additional 400 shares in the last quarter. 50.01% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Guidelines for Successful Channel Trading
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.